**Gastrointestinal**

**Neuroendocrine Tumors**

**Well Differentiated**

1st Line

Operable

**NET0030**
- Pilot Phase 1 Study of Perioperative Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic, WHO Grade 1 or 2, SSTR Positive, Gastroenteropancreatic Neuroendocrine Tumors
  - PI: Visser
  - Pending
  - 1st Priority

Inoperable

**NET0028**
- Phase III 177Lu-Edotetide vs Targeted Molecular Therapy w/ Everolimus in SSTR+ Neuroendocrine Tumours
  - PI: Aparici
  - Sponsor: ITM Solucin GmbH

**NET0032**
- Phase III Peptide Receptor Radionuclide Tx w/ Lu-Edotetide vs SoC in SSTR+ Neuroendocrine Tumors
  - PI: Igaru
  - Sponsor: ITM Solucin GmbH

2nd Line

**ECOG-ACRIN A021602**
- Phase III Cabozantinib vs Placebo in Advanced Neuroendocrine Tumors After Progression on Everolimus
  - PI: Shabgut
  - Sponsor: Cinetics Pharmaceuticals, Inc.

**NET0033**
- Randomized Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Pallumotide Treatment in Carcinoid Syndrome
  - PI: Shahnaz
  - Sponsor: Cinetics Pharmaceuticals, Inc.